Genome Editing Market Research Report Information By Technology (Meganucleases, (CRISPR)/Cas9, TALENs/MegaTALs, ZFN, Others), By Delivery Method (Ex-vivo, In-vivo), By Mode (Contract, In-house), By End-use (Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes, Contract Research Organizations), By Application (Genetic Engineering, Cell Line Engineering, Animal Genetic Engineering, Plant Genetic Engineering, Others), By Clinical Applications (Diagnostics, Therapy Development), And By Region (North America, Europ

Global Genome Editing Market Overview

Genome Editing Market Size was valued at USD 6.6 Billion in 2022. The genome editing market industry is projected to grow from USD 7.26 Billion in 2023 to USD 15.69 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 10.10% during the forecast period (2023 - 2032). Increased developments in genome editing and increased application areas of genomics are the key market drivers enhancing the market growth.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Genome Editing Market Trends

• Advancements in CRISPR technology is driving the market growth

In the genome editing market, a prominent trend revolves around the continuous advancements in Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology. CRISPR has revolutionized genome editing with its precision and efficiency, allowing researchers to target specific genes for modification. The ongoing refinement of CRISPR techniques, including base editing and prime editing, enhances the accuracy and versatility of gene editing processes. This trend underscores the relentless pursuit of more effective and targeted genome editing tools, opening new avenues for therapeutic applications and research breakthroughs. This factor drives the market CAGR.

Additionally,a significant trend shaping the genome editing market is the increasing focus on therapeutic applications and gene therapies. As our understanding of the genetic basis of diseases deepens, there is a growing emphasis on utilizing genome editing tools for treating genetic disorders and other medical conditions at the molecular level. Researchers and biotech companies are exploring CRISPR-based therapies, including gene replacement, gene correction, and gene silencing, to develop innovative treatments for a spectrum of diseases. This trend reflects the transformative potential of genome editing in personalized medicine and the pursuit of more targeted and curative healthcare solutions.

An emerging trend in the genome editing market involves heightened attention to ethical and regulatory considerations surrounding the application of gene-editing technologies. As the field progresses, there is a growing awareness of the ethical implications related to editing the human germ line and potential unintended consequences. Governments and regulatory bodies are actively working to establish guidelines and regulations to ensure responsible use and mitigate ethical concerns. This trend underscores the importance of balancing scientific progress with ethical considerations, establishing a framework for the responsible development and application of genome editing technologies.For instance, in November 2021, Precision BioSciences, Inc. and Eli Lilly partnered to create potential in-vivo therapies for genetic illnesses using the latter company's unique ARCUS genome editing platform.Thus, driving the genome editing market revenue.

Genome Editing Market Segment Insights

Genome editingTechnology Insights

The genome editing market segmentation, based on Technology includes Meganucleases, (CRISPR)/Cas9, TALENs/MegaTALs, ZFN, Others. The dominant technology is CRISPR/Cas9 due to its revolutionary precision, efficiency, and versatility in targeting specific genes for modification. CRISPR's widespread adoption is fueled by its simplicity, cost-effectiveness, and ability to induce targeted genetic changes across diverse organisms. The fastest-growing category is Meganucleases, known for their natural DNA-binding proteins with high specificity. The interest in Meganucleases stems from their potential application in therapeutic gene editing, where precision is paramount.

Genome editing Delivery Method Insights

The genome editing market segmentation, based on Delivery Method, includes Ex-vivo, In-vivo. The dominant category is in-vivo, primarily due to its direct application within the living organism, offering the potential for targeted and systemic genome modifications. The fastest-growing category, however, is ex-vivo delivery, particularly in therapeutic applications like gene therapies and personalized medicine. Ex-vivo methods involve editing genes outside the body, such as in isolated cells, before reintroducing them to the organism.

Genome editing Mode Insights

The genome editing market segmentation, based on mode, includes Contract, In-house. The dominant category is in-house, reflecting a preference for maintaining control and confidentiality over research and development processes. In-house capabilities empower organizations to have direct oversight, enabling them to tailor genome editing projects to specific objectives and timelines. Conversely, the fastest-growing category is contract genome editing services. As the demand for genome editing expertise rises, organizations increasingly opt for external partnerships to access specialized knowledge and technologies.

Genome editing End-use Insights

The genome editing market segmentation, based on End-use, includes Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes, and Contract Research Organizations. The dominant category is Biotechnology & Pharmaceutical Companies, reflecting the industry's significant investments in advancing genomic technologies for therapeutic and research purposes. Conversely, the fastest-growing category is Academic & Government Research Institutes. As genomic research becomes increasingly collaborative and interdisciplinary, academic institutions and government research entities contribute to the rapid growth by exploring diverse applications of genome editing, fostering scientific discoveries, and serving as hubs for foundational research.

Figure 1: Genome Editing Market, by End-Use, 2022 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Genome editing Application Insights

The genome editing market segmentation, based on application, includes Genetic Engineering, Cell Line Engineering, Animal Genetic Engineering, Plant Genetic Engineering, Others. The dominant category is genetic engineering, where genome editing technologies are extensively employed for manipulating and modifying genes in various organisms. Genetic engineering applications include creating genetically modified organisms, studying gene functions, and advancing agricultural practices. On the other hand, the fastest-growing category is Clinical Applications. With an increasing focus on precision medicine and personalized therapies, genome editing finds rapid adoption in clinical settings.

Genome editing Clinical Applications Insights

The genome editing market segmentation, based on application, includes Diagnostics, Therapy Development. The dominant category is therapy development. Within the genome editing market, the therapeutic development segment included a range of strategies intended to cure genetic abnormalities, malignancies, infectious illnesses, and other ailments by using genome editing instruments including CRISPR-Cas9, TALENs, and zinc finger nucleases. There has been a substantial investment in genome editing research and development, including the creation of therapies, because to the increased interest from both the public and private sectors.

Genome editing Regional Insights

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American genome editingmarket area will dominate this market, owing to fostering innovation and the rapid adoption of cutting-edge genomic technologies. In addition, the growing number of establishing health clubs and fitness facilities will boost market growth in this region.

Further, the major countries studiedin the market reportare The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure2:GENOME EDITINGMARKET SHARE BY REGION 2022 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe genome editing market accounts for the second-largest market share due to the robust research environment fosters innovation and the development of advanced genome editing technologies. Further, the German genome editing market held the largest market share, and the UK genome editing market was the fastest growing market in the European region

The Asia-Pacific Genome Editing Market is expected to grow at the fastest CAGR from 2023 to 2032. This is due to increasing investment in genomics research and genetic engineering technologies foster a conducive environment for the adoption of genome editing applications. Moreover, China’s genome editing market held the largest market share, and the Indian genome editing market was the fastest growing market in the Asia-Pacific region.

Genome editing Key Market Players & Competitive Insights

Leading market players are investing heavily in research and development in order to expand their product lines, which will help the genome editing market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, genome editingindustry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the genome editing industry to benefit clients and increase the market sector. In recent years, the genome editingindustry has offered some of the most significant advantages. Major players in the genome editing market, including Merck KGaA, Cibus, Recombinetics, Inc., Sangamo, Editas Medicine, Precision Biosciences, CRISPR Therapeutics, Intellia Therapeutics, Inc.,Caribou Biosciences, Inc.,Cellectis S.A.,AstraZeneca,Takara Bio USA,Horizon Discovery Group plc, and others, are attempting to increase market demand by investing in research and development operations.

Precision BioSciences is a biotechnology company specializing in genome editing. Precision BioSciences is known for its ARCUS genome editing platform, which is designed to create specific and efficient modifications to the DNA of living organisms. The company has applications in areas such as gene therapy, agriculture, and cell therapy.In November 2021, Precision BioSciences, Inc. and Eli Lilly partnered to create potential in-vivo therapies for genetic illnesses using the latter company's unique ARCUS genome editing platform.

Intellia Therapeutics, Inc. is a biotechnology company focused on developing and commercializing CRISPR/Cas9 gene editing technology for therapeutic applications. The company aims to leverage the CRISPR technology to develop potentially curative treatments for genetic diseases. Intellia Therapeutics is involved in various research and development activities related to genome editing and has collaborations with other pharmaceutical companies. n February 2022, Intellia Therapeutics, Inc. and Regeneron Pharmaceuticals, Inc. announced the positive interim data from an ongoing Phase I clinical study of their lead in vivo genome editing candidate, NTLA-2001 (Investigational Crispr Therapy For Transthyretin (Attr) Amyloidosis).

Key Companies in the genome editing market include

• Merck KGaA


• Cibus


• Recombinetics, Inc.


• Sangamo


• Editas Medicine


• Precision Biosciences


• CRISPR Therapeutics


• Intellia Therapeutics, Inc.


• Caribou Biosciences, Inc.


• Cellectis S.A.


• AstraZeneca


• Takara Bio USA


• Horizon Discovery Group plc

Genome editingIndustry Developments

Genome Editing Market Segmentation

Genome editing Technology Outlook (USD Billion, 2018-2032)

• Meganucleases


• (CRISPR)/CAS9


• TALENs/MegaTALs


• ZFN


• Others

Genome editing Delivery Method Outlook (USD Billion, 2018-2032)

• Ex-vivo


• In-vivo

Genome editing Mode Outlook (USD Billion, 2018-2032)

• Contract


• In-house

Genome editing End-use Outlook (USD Billion, 2018-2032)

• Biotechnology & Pharmaceutical Companies


• Academic & Government Research Institutes


• Contract Research Organizations

Genome editing Application Outlook (USD Billion, 2018-2032)

• Genetic Engineering


• Cell Line Engineering


• Animal Genetic Engineering


• Plant Genetic Engineering


• Others

Genome editing Clinical Applications Outlook (USD Billion, 2018-2032)

• Diagnostics


• Therapy Development

Genome editing Regional Outlook (USD Billion, 2018-2032)

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America